PBLA — Panbela Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.17m
- $7.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.
Directors
- Michael Cullen CHM (75)
- Jennifer Simpson PRE (52)
- Jeffrey Mathiesen VCH (60)
- Susan Horvath CFO (61)
- Suzanne Gagnon OTH (64)
- Arthur Fratamico IND (55)
- Paul Schaffer IND (78)
- Donald Schemel IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- September 21st, 2011
- Public Since
- July 29th, 2014
- No. of Shareholders
- 55
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,854,831
- Address
- 712 Vista Blvd # 305, WACONIA, 55387
- Web
- https://panbela.com/
- Phone
- +1 9524791196
- Contact
- James Carbonara
- Auditors
- Cherry Bekaert LLP
Upcoming Events for PBLA
Q1 2025 Panbela Therapeutics Inc Earnings Release
Q2 2025 Panbela Therapeutics Inc Earnings Release
Similar to PBLA
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Panbela Therapeutics share price?
As of Today at 22:33 UTC, shares in Panbela Therapeutics are trading at $0.24. This share price information is delayed by 15 minutes.
How has the Panbela Therapeutics share price performed this year?
Shares in Panbela Therapeutics last closed at $0.24 and the price had moved by -37.06% over the past 365 days. In terms of relative price strength the Panbela Therapeutics share price has underperformed the S&P500 Index by -41.64% over the past year.
What are the analyst and broker recommendations for Panbela Therapeutics?
The overall consensus recommendation for Panbela Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Panbela Therapeutics dividend yield?
Panbela Therapeutics does not currently pay a dividend.
Does Panbela Therapeutics pay a dividend?
Panbela Therapeutics does not currently pay a dividend.
When does Panbela Therapeutics next pay dividends?
Panbela Therapeutics does not currently pay a dividend.
How do I buy Panbela Therapeutics shares?
To buy shares in Panbela Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Panbela Therapeutics?
As of the previous close price of $0.24, shares in Panbela Therapeutics had a market capitalisation of $1.17m.
Where are Panbela Therapeutics shares listed?
Here are the trading details for Panbela Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PBLA
What kind of share is Panbela Therapeutics?
Based on an overall assessment of its quality, value and momentum Panbela Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Panbela Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Panbela Therapeutics is $500.00. That is 208233.33% above the last closing price of $0.24.
Analysts covering Panbela Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.36 for the next financial year.
Find out moreWhat is the trend in the Panbela Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Panbela Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -34.96%.
As of the last closing price of $0.24, shares in Panbela Therapeutics were trading -31.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Panbela Therapeutics PE Ratio?
The Panbela Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Panbela Therapeutics?
Panbela Therapeutics' management team is headed by:
- Michael Cullen - CHM
- Jennifer Simpson - PRE
- Jeffrey Mathiesen - VCH
- Susan Horvath - CFO
- Suzanne Gagnon - OTH
- Arthur Fratamico - IND
- Paul Schaffer - IND
- Donald Schemel - IND